View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 11, 2018

Xspray Pharma reports positive results from HyNap-Dasa Phase I study

Xspray Pharma has reported positive data from a Phase I study of HyNap-Dasa in comparison with Sprycel for the treatment of cancer, after meeting the trial's primary goal.

Xspray Pharma has reported positive data from a Phase I study of HyNap-Dasa in comparison with Sprycel for the treatment of cancer, after meeting the trial’s primary goal.

The trial compared the pharmacokinetic parameters, including Cmax and area under the curve (AUC), for Sprycel and two different HyNap tablet formulations of dasatinib.

During the trial, a total of 16 healthy subjects received single doses of each of the study product in a cross-over design.

Results from the trial have validated its primary aim to demonstrate bioequivalence of an optimised formulation of HyNap-Dasa against Sprycel, a dasatinib chemotherapy medication that is currently being marketed for the treatment of chronic myeloid leukaemia (CML).

Xspray Pharma said that it will leverage the results to design its planned registration study for an abbreviated new drug application (ANDA) of the US Food and Drug Administration (FDA).

“It signifies a new and important step in our development as a company.”

Xspray Pharma CEO Per Andersson said: “The outcome of this study represents an important milestone for Xspray Pharma as it means that we now can initiate the preparation of the pivotal phase of the clinical programme, taking us closer to a commercial launch of HyNap-Dasa.

“Furthermore, the results pave the way also for additional product candidates in our pipeline. It signifies a new and important step in our development as a company.”

Xspray Pharma uses its RightSize technology to develop improved and generic versions of available cancer drugs, primarily protein kinase inhibitors (PKIs) for use in the treatment of cancer.

The company has identified three PKIs as the first product candidates, including HyNap-Dasa, HyNap-Sora and HyNap-Nilo.

Related Companies

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena